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 1. Introduction 
Despite several improvements in diagnosis and treatment,
deﬁcits in real life functioning, such as independent living,
social functioning and remunerative employment, persist in
most people with schizophrenia ( Fleischhacker et al., 2014;
Velthorst et al., 2017 ). 
Negative symptoms represent one the most important
contributors to disability ( Ergul and Ucok, 2015; Galderisi
et al., 2014 , 2017 , 2018a; Marder and Galderisi, 2017;
Quinlan et al., 2014; Strauss et al., 2012b; Ventura et al.,
2015 ). Even low levels of negative symptoms were found
to predict real-life functional impairment ( Strassnig et al.,
2018 ). 
Primary negative symptoms seem to be resistant to most
psychopharmacological treatments and rehabilitation inter-
ventions ( Keshavan et al., 2017; Sarkar et al., 2015; Talpos,
2017; Veerman et al., 2017 ). Therefore, to date, negative
symptoms in schizophrenia remain a signiﬁcant unmet need
( Galderisi et al., 2018a; Marder and Galderisi, 2017 ). 
The heterogeneity of negative symptoms and the lim-
itations in their deﬁnition and assessment might have of Geneva Hospitals, Geneva, 
f Oslo and Oslo University Hospital, Oslo, 
Sciences, Poznan, Poland 
ty of Vienna, Vienna, Austria 
gram, Istanbul University, Istanbul, 
accepted 29 May 2019 
n unmet need of treatment in schizophrenia. Although a con-
om construct, and second generation assessment instruments
ilable, studies still rely upon old assessment instruments, that
alizations and might limit progress in the search for effective
se in the European context, where one of the challenges en-
udies is the availability of validated instruments in the many
address this challenge and promote sound research on nega-
CNP Schizophrenia Network coordinated a large multicenter,
f the Brief Negative Symptom Scale (BNSS). Clinically-stable
Z, N = 249) were recruited from 10 European Countries. Apart
istered the Positive and Negative Syndrome Scale (PANSS) and
pression, extrapyramidal symptoms and psychosocial function-
t internal consistency, convergent and discriminant validity of
odel. A larger number of subjects with predominant negative
lation for clinical trials, was identiﬁed by using the BNSS com-
 analysis showed that BNSS-avolition, a key negative symptom
ned 23.9% of psychosocial functioning, while no combination of
ms showed the same impact on functioning. The study demon-
l advantages with respect to PANSS for the identiﬁcation of the
ith predominant negative symptoms. 
Author(s). Published by Elsevier B.V.
ess article under the CC BY-NC-ND license.
icenses/by-nc-nd/4.0/ ) 
contributed to the lack of signiﬁcant progress in developing
effective therapeutic interventions ( Galderisi et al., 2018a ).
In 2005, the National Institute of Mental Health (NIMH)-
MATRICS consensus statement on negative symptoms de-
ﬁned the constructs to be regarded as part of the negative
symptom dimension ( Kirkpatrick et al., 2006; Kirkpatrick
and Fischer, 2006 ). The consensus statement identiﬁed ﬁve
main domains of the negative symptoms: anhedonia, avoli-
tion, blunted affect, alogia, and asociality ( Blanchard and
Cohen, 2006; Horan et al., 2011; Kirkpatrick et al., 2006 ,
2011; Kring et al., 2013; Millan et al., 2014 ). Subsequently,
several factor analysis studies showed that the ﬁve con-
structs listed above clustered into two independent dimen-
sions: avolition/apathy (including avolition, asociality and
anhedonia) and expressive deﬁcit (including blunted affect
and alogia) ( Bischof et al., 2016; Jang et al., 2016; Kimhy
et al., 2006; Mucci et al., 2015; Nakaya and Ohmori, 2008;
Strauss et al., 2013 ). 
The two-factor solution has been identiﬁed in subjects
with primary negative symptoms (deﬁcit schizophrenia) and
in those with a combination of primary and secondary
A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale 949 
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b  egative symptoms, especially after excluding items unre- 
ated to negative symptoms, such as inattentiveness or in- 
ppropriate affect ( Blanchard and Cohen, 2006; Galderisi 
t al., 2013a , 2018a; Kimhy et al., 2006; Kirkpatrick et al.,
011; Kring et al., 2013; Mucci et al., 2015; Nakaya and
hmori, 2008; Strauss et al., 2013 ). 
The two dimensions are independent of medication 
 Kelley et al., 1999; Tremeau et al., 2008 ) and have been
ross-culturally validated ( Bischof et al., 2016; Mane et al.,
014; Mucci et al., 2015; Strauss et al., 2012a ). 
However, some ﬁndings have questioned the two factors 
olution ( Ahmed et al., 2018; Garcia-Portilla et al., 2015; 
trauss et al., 2018a , 2018b ) in particular, a large, multi-
entric study in subjects with schizophrenia, using the BNSS 
o assess negative symptoms, suggested that a ﬁve-domain 
onstruct might have better ﬁt statistics ( Ahmed et al.,
018; Strauss et al., 2018a, 2018b ). These latter ﬁndings 
wait independent replications. 
It is widely recognized that primary negative symptoms 
re related to the core pathophysiology of schizophrenia 
nd represent the true unmet need of schizophrenia treat- 
ent. Secondary negative symptoms, due to other identi- 
able causes such as positive symptoms, depression, ex- 
rapyramidal side effects of antipsychotic drugs or isola- 
ion, should thus be excluded in studies aiming to inves- 
igate the pathophysiology of negative symptom domains 
r to test new treatment effects ( Carpenter et al., 1985;
alderisi et al., 2018a; Kirschner et al., 2017; Mucci et al.,
017; Treen et al., 2019 ). 
For clinical trials targeting negative symptoms regulatory 
gencies require the exclusion of main confounding factors, 
uch as high severity of positive and depressive symptoms, 
s well as parkinsonism ( EMA, 2012; Marder et al., 2011 ).
wo main concepts were proposed to address the issue of
seudospeciﬁc effects on negative symptoms in clinical tri- 
ls ( Buchanan, 2007; Mucci et al., 2017 ): the “predominant
egative symptoms” (with negative symptoms more severe 
han positive ones combined with a threshold for depres- 
ive symptoms or parkinsonism), and the “persistent nega- 
ive symptoms” (in which a maximum threshold for positive 
ymptoms, depression and parkinsonism on validated scales 
s deﬁned). The latter concept also requires a stability over 
 months for the negative symptoms of moderate severity. 
The advantages of newly developed scales over those 
argely used in the past, such as the Positive and Negative
yndrome Scale (PANSS) – Negative subscale, have not been 
ystematically investigated. 
The availability of validated state of the art instruments 
s of crucial importance in large multicenter, multinational 
tudies, which represent the standard context of clinical tri- 
ls. The validation should also demonstrate that the new 
cale identiﬁes a comparable or a larger number of subjects 
ith negative symptoms of moderate severity in samples 
ith and without confounding factors (i.e., severe positive 
ymptoms, depression or parkinsonism). Finally, a larger im- 
act on functional outcome of the negative symptoms iden- 
iﬁed by the new scale, in comparison with those identiﬁed
y established scales, should be demonstrated. 
The purposes of our study were: (1) to validate the
NSS within a large European multicenter, multinational 
nd multilingual study carried out in stabilized subjects 
ith schizophrenia, demonstrating the convergent and iscriminant validity with respect to established rating 
cales to assess negative, positive and depressive symp- 
oms, namely the PANSS and the Calgary Depression Rating
cale for schizophrenia (CDSS); (2) to investigate the fre-
uency of negative symptoms in subjects with and with-
ut confounding factors; (3) to evaluate whether the new
cale identiﬁes more subjects with core negative symptoms 
n both groups and (4) to investigate the impact on func-
ional outcome of core negative symptoms as identiﬁed by
he BNSS or the PANSS, controlling for major confounding
actors. 
. Experimental procedures 
.1. Participants 
he European College of Neuropsychopharmacology (ECNP) Net- 
ork on Schizophrenia Study on the Assessment of Negative Symp-
oms (ENSANeS) was carried out within the activities of the ECNP
chizophrenia Network. 
Study participants were recruited among subjects attending the
utpatient and inpatient units of the Psychiatric Departments of 12
uropean centers (see appendix for the list of the centers). 
Recruitment was carried out from October 31, 2016 to July 15,
017. 
Inclusion criteria were a diagnosis of schizophrenia according 
o DSM-IV, conﬁrmed by the Mini Neuropsychiatric Interview-Plus
MINI-Plus), and an age between 18 and 65 years. 
Exclusion criteria were: (a) treatment modiﬁcations and/or hos-
italization due to symptom exacerbation in the last three months;
b) a history of moderate to severe intellectual disability or of neu-
ological diseases; (c) a history of alcohol and/or substance abuse
n the last six months; (d) current pregnancy; and (e) inability to
rovide an informed consent. 
The local Ethics Committee of the involved institutions approved
he study, and the study was performed in accordance with the eth-
cal standards laid down in the 1964 Declaration of Helsinki. 
All participants signed a written informed consent to participate
n the study, after receiving a detailed explanation of the study
rocedures and goals. 
.2. Assessment 
.2.1. Demographic and clinical information 
n ad-hoc form was ﬁlled in with data on age, gender, race, edu-
ation (number of years at school), paternal and maternal educa-
ion (number of years at school), as well as clinical information,
uch as family history of schizophrenia-spectrum disorders or ma-
or mood disorders (bipolar and major depressive disorders with or
ithout psychotic features), duration of illness, number of hospital-
zation, type and dosage of antipsychotic medications and concomi-
ant medications, using all the available sources of information. 
The daily antipsychotic dose was converted to olanzapine equiv-
lents dose based on deﬁned daily doses (DDDs), according to the
orld Health Organization’s Collaborative Center for Drug Statistics 
ethodology ( Leucht et al., 2016 ). 
.2.2. Psychopathological assessment 
he Brief Negative Symptom Scale (BNSS; Kirkpatrick et al., 2011 ),
eveloped after the MATRICS consensus initiative ( Kirkpatrick 
t al., 2006 ), was used to assess negative symptom domains. The
NSS is a semi-structured interview with 13 items, organized into
 negative symptom subscales (anhedonia, asociality, avolition, 
lunted affect and alogia), plus and additional subscale including
950 A. Mucci, A. Vignapiano and I. Bitter et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 one item assessing the lack of the normal experience of distressing,
unpleasant emotions, which was included to help the distinction
of primary from secondary negative symptoms ( Kirkpatrick et al.,
2011; Mucci et al., 2015 ). 
For all items higher scores are associated with greater impair-
ment/presence of symptoms. A scale total score is calculated by
summing up the 13 individual items; subscale scores are calculated
by summing up the individual items within each subscale. The dis-
tress subscale, that quantiﬁes the absence of distress, is treated
in the same manner as the other subscales. It is not included
in the core negative symptom domains ( Kirkpatrick et al., 2006 )
and does not consistently load on the negative symptom factors
( Kirkpatrick et al., 2006 , 2011; Mucci et al., 2015; Ahmed et al.,
2018 ). 
All non-English versions of the BNSS were developed using the
translation–backtranslation method. The translated versions were
back-translated into English by a native speaker of the same lan-
guage in which the scale was developed. The back-translated ver-
sions were reviewed and approved by Brian Kirkpatrick or Gre-
gory Strauss who participated in the development of the scale
( Kirkpatrick et al., 2011 ). 
The Positive and Negative Syndrome Scale (PANSS; Kay et al.,
1987) is one of the most widely used instruments to investigate
psychopathology in schizophrenia. The scale includes a subscale
for positive symptoms; a subscale for negative symptoms, that in-
cludes 2 symptoms recently excluded, i.e., difﬁculty in abstract
thinking and stereotyped thinking, as both of them are part of the
cognitive dimension; and a general psychopathology scale with 16
items. According to the ﬁve-factor model proposed by Wallwork
et al. (2012) , we computed the positive dimension by summing
up the scores on the items “Delusions” (P1), “Hallucinatory behav-
ior” (P3), “Grandiosity” (P5) and “Unusual thought content” (G9),
and the disorganization dimension by summing up the three PANSS
items: “Conceptual disorganization” (P2), “Difﬁculty in abstract
thinking” (N5), and “Poor attention” (G11). 
To compare the ability of BNSS and PANSS-negative subscale
(PANSS-NEG) to identify core negative symptoms and assess the im-
pact of identiﬁed negative symptoms on functional outcome we
used the 5 subscales of BNSS (alogia, anhedonia, avolition, aso-
ciality and blunted affect) and the 5 core negative symptoms of
the PANSS (blunted affect, emotional withdrawal, poor rapport,
passive-apathetic social withdrawal, and lack of spontaneity and
ﬂow of conversation). 
The CDSS ( Addington et al., 1993) was used to assess depressive
symptoms. Ratings > 6 on the total score indicate clinically signif-
icant depression. Non-English versions of the CDSS are available on
the ofﬁcial website ( http://www.ucalgary.ca/cdss/ ). 
The SHSR ( Gerlach et al., 1993) was used to quantify the pres-
ence of extrapyramidal symptoms. Clinically signiﬁcant parkinson-
ism, which might confound the assessment of negative symptoms,
is deﬁned by a “mild” (2) rating on at least three items, or a “mild”
rating for tremor or rigidity plus a “mild” rating on at least an-
other item, or a “mild-moderate” (3 or more) rating on at least one
item. 
Bradykinesia and reduction of facial expression have not been
evaluated as confounding factors since they could be an aspect of
negative symptoms ( Walther and Strik, 2012 ). 
Raters were research staff members of the participating cen-
ters. All raters had extensive prior experience in conducting clin-
ical interviews, but the inter-rater reliability across the sites was
not evaluated for the present study. 
2.2.3. Functional outcome 
Personal and Social Performance (PSP) scale ( Morosini et al., 2000 )
was used to evaluate the functional outcome. The PSP is a 0–100
single-item rating scale, in which higher scores indicate better
functioning. 2.3. Assessment of frequency of at least moderate 
severity negative symptoms 
As the European Medicines Agency (EMA) guidelines on clinical trial
design for negative symptoms require the inclusion of subjects with
at least moderate severity negative symptoms, deﬁned on an ac-
cepted and validated rating scale, we investigated the frequency
of these symptoms using both the BNSS and the PANSS. For the
BNSS a score ≥ 3 (moderate) was necessary on each of the 5 BNSS
subscales for core negative symptoms; for PANSS a score ≥4 (mod-
erate) for the following core negative symptoms: Blunted Affect
(N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive social
withdrawal (N4) and Lack of Spontaneity (N6). 
2.4. Statistical analysis 
2.4.1. Internal consistency, convergent and discriminant 
validity 
Data distributions were examined for normality and homogeneity
of variance and presence of outliers (subjects whose scores ex-
ceeded the 75th or the 25th percentile by 1.5 times the interquar-
tile range). 
The demographic and clinical characteristics of study partici-
pants were summarized as mean ± Standard Deviation (SD) and
percentages where appropriate. 
The construct validity of the BNSS was analyzed by assessing its
internal consistency and convergent and discriminant validity, as
reported in previous papers ( Kirkpatrick et al., 2011; Mucci et al.,
2015; Strauss et al., 2012a ). Internal consistency across all items of
the BNSS was assessed using the Cronbach’s alpha value. 
Convergent validity was evaluated by examining the association
of the BNSS total score with the PANSS negative subscale score,
which measures the same construct, and PANSS total score, as the
latter includes the negative subscale score and thus should be at
least moderately correlated with the BNSS total. Discriminant va-
lidity was assessed by examining correlations of the BNSS total score
with PANSS positive subscale score and CDSS total score. The Spear-
man rho was used for correlations as score distributions deviated
from normality for the scales. With large sample size ( N > 200), p
values are generally highly signiﬁcant even for very low correlation
coefﬁcients ( r = 0.10, p < 0.01); for this reason, the absolute value
of the correlation coefﬁcient is a more conservative estimation of
association. Correlation coefﬁcients (in absolute value) < 0.35 are
generally considered to represent low or weak correlations, those
from 0.36 to 0.67 modest to moderate correlations, and those from
0.68 to 1.0 strong correlations ( Evans, 1996 ). 
2.4.2. Factor structure of the BNSS 
The factor structure of the BNSS was examined using a conﬁrma-
tory factor analysis (CFA), in order to evaluate the ﬁt of 4 models of
the latent structure of negative symptoms (Figs. S1–S4), according
to Strauss et al. (2018a) and Ahmed et al. (2018) . The ﬁrst model
(unidimensional model) evaluated whether all ﬁve domains (avo-
lition, anhedonia, asociality, blunted affect and alogia) reﬂected
a single negative symptom structure (Fig. S1); the second model
(Fig. S2) considered the two negative symptom dimensions: moti-
vation and pleasure (MAP) and expressive deﬁcit (EXP); the third
model tested the 5-factor model of negative symptoms (Fig. S3);
ﬁnally the fourth model (hierarchical model) (Fig. S4) was designed
with 5 ﬁrst-order factors (ﬁve negative symptom domains) and
2 second-order factors (MAP and EXP). In all the CFA models the
item “Lack of normal distress” was not included because it was
not part of the NIMH consensus conference domains, and prior ex-
ploratory factor analysis studies reported low communalities for
this item ( Strauss et al. 2012a; Mucci et al., 2015 ). 
A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale 951 
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Table 1 Demographic and illness-related variables of the 
study sample (SCZ = 249). 
N % 
Gender § (% males) 158 63.5 
Caucasian § (%) 202 81.1 
Antipsychotic treatment (%) 
First generation 14 5.6 
Second generation 193 77.5 
Both 27 10.8 
None 13 5.2 
N/A 4 0.8 
N Mean ± SD 
Age (years) 249 37.3 ± 11.3 
Education (completed years) 249 12.9 ± 3.2 
Duration of illness (years) 249 12.4 ± 9.1 
Olanzapine equivalent dose 232 14.75 ± 9.29 
PANSS total 240 61.21 ± 17.20 
PANSS positive 244 13.1 ± 5.3 
PANSS negative 247 17.54 ± 16.62 
PANSS disorganization 246 6.70 ± 2.83 
BNSS total 246 26.5 ± 15.5 
Anhedonia subscale 248 6.31 ± 4.67 
Asociality subscale 249 4.20 ± 2.58 
Avolition subscale 249 4.58 ± 3 
Blunted affect subscale 249 6.71 ± 4.43 
Alogia subscale 249 3.20 ± 3.09 
CDSS total 236 3.5 ± 3.6 
SHRS Parkinsonism total 248 3.78 ± 5.0 
PSP total 234 57.38 ± 15.32 
SCZ = subjects with schizophrenia; PANSS = Positive and Neg- 
ative Syndrome Scale; CDSS = Calgary Depression Scale for 
Schizophrenia; SHRS = St. Hans Rating Scale; BNSS = Brief Neg- 
ative Symptom Scale; PSP = Personal and Social Performance 
scale; § – Data not available for one of the participant centers. 
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(To assess the global ﬁt, the following indices were applied: χ2
alue, the comparative ﬁt index (CFI), the Tucker Lewis index (TLI),
he root mean square error of approximation (RMSEA), the Akaike
nformation criterion (AIC) and the sample size-adjusted Bayesian 
nformation criterion (BIC). The information criteria, AIC and BIC, 
re relative ﬁt indices of model parsimony that take into account
odel complexity based on degrees of freedom. Lower values indi-
ate better model ﬁt. A good ﬁt included a χ2 value not statistically
igniﬁcant, CFI and TLI values of at least 0.95, RMSEA no greater
han 0.08 and lower BIC and AIC values. 
.4.3. Frequency of negative symptoms of at least moderate 
everity 
requencies of at least one negative symptom of moderate sever-
ty, assessed using the PANSS and the BNSS, were calculated for
ach BNSS subscale assessing core negative symptoms (i.e., exclud- 
ng “Distress”) and PANSS ﬁve core negative symptom items in the
hole SCZ sample and in male and female subgroups. Furthermore,
ubjects were divided in those with and without confounding fac-
ors based on the following thresholds: positive symptoms (P1, P3,
5, P6, G9) and disorganization (P2) score > 4 on the PANSS, CDSS
otal score > 6 ( Addington et al., 1993 ) and presence of parkinson-
sm evaluated with SHRS as outlined above. In these groups, the
requency of at least 1, 2 and 3 negative symptoms of moderate
everity was assessed. 
.4.4. Association of core negative symptoms with functional 
utcome 
he association of core negative symptoms with functional outcome
as studied using multiple stepwise linear regression. 
Separate stepwise multiple regressions were conducted for neg- 
tive symptoms assessed using the 5 BNSS domains or the 5 core
ANSS items as previously deﬁned. 
For each regression analysis, the PSP total score was the depen-
ent variable, while the independent predictors were age, gender, 
ducation, duration of illness, olanzapine equivalent dose, PANSS 
isorganization and positive dimensions, depression, SHRS Parkin- 
onism, and scores on BNSS subscales (anhedonia, avolition, aso- 
iality, blunted affect and alogia) or scores on PANSS core negative
tems (Blunted Affect, Emotional Withdrawal, Poor Rapport, Passive 
ithdrawal and Lack of Spontaneity). 
Statistical signiﬁcance level was set at p ≤ 0.05 for all tests. 
Conﬁrmatory factor analyses (maximum likelihood) were esti- 
ated using AMOS 21.0. All other analyses were carried out using
PSS 22 (IBM Corp, Armonk, NY). 
. Results 
.1. Sociodemographic and clinical variables 
wo hundred forty-nine subjects with a DSM-IV diagno- 
is of schizophrenia were enrolled. Data on demographic 
nd illness related variables are provided in Table 1 . En-
olled subjects were predominantly males, with a mean 
ge of 37 years, with a mean education level of 13 years,
ll in a chronic phase of the illness. Almost all subjects
ith schizophrenia were treated with antipsychotics (94%), 
ostly with second-generation antipsychotics ( Table 1 ). 
.2. BNSS internal consistency, construct validity 
nd factor models 
wo hundred thirty-six subjects with schizophrenia had a 
omplete data set with respect to the considered measures sed to assess BNSS internal consistency, construct validity 
nd its factor structure. 
Cronbach’s alpha, calculated to examine internal con- 
istency, was 0.94, indicating high internal consistency of 
NSS. 
BNSS total score was signiﬁcantly correlated with the 
ANSS negative subscale score ( ρ = 0.77) and was moder-
tely associated with PANSS total score ( ρ = 0.57) in the
hole sample of subjects with schizophrenia. Convergent 
alidity was assessed also in the subsample without clin-
cally signiﬁcant parkinsonism and/or depression including 
64 subjects; we found a strong correlation with the PANSS
egative subscale score ( ρ = 0.76) and a moderate associa-
ion with PANSS total score ( ρ = 0.61). These correlations
onﬁrm that both scales assess a similar underlying con-
truct of negative symptoms ( Table 2 ). 
As to the discriminant validity, the BNSS total score
howed weak correlations with the PANSS positive sub- 
cale ( ρ = 0.21) and with CDSS total score ( ρ = 0.27) in the
hole sample. In the subsample without confounding fac- 
ors, the correlation was weak with the PANSS positive sub-
cale ( ρ = 0.23) and extremely weak with CDSS total score
 ρ = 0.13). 
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Table 2 BNSS convergent and discriminant validity (rho-values) in the main sample ( n = 236) and in the subsample without 
confounding factors § ( n = 136). 
BNSS total score 
(main sample) 
p value BNSS total score (subsample without 
depression and extrapyramidal symptoms) 
p value 
Convergent validity 
PANSS negative subscale 0.77 ∗∗∗ < 0.0001 0.76 ∗∗∗ < 0.0001 
PANSS total score 0.57 ∗∗ < 0.0001 0.61 ∗∗ < 0.0001 
Discriminant validity 
PANSS positive subscale 0.21 ∗ < 0.001 0.23 ∗ 0.003 
CDSS total score 0.27 ∗ < 0.0001 0.13 0.08 
BNSS: Brief Negative Symptom Scale; PANSS: Positive and Negative Syndrome Scale; CDSS: Calgary Depression Scale for Schizophrenia. 
§ Confounding factors = clinically signiﬁcant levels of depression (CDSS total > 6), extrapyramidal symptoms (parkinsonism on the St. Hans 
scale) and positive or disorganization symptoms ( > 4 on the PANSS). 
With large sample size ( N > 200), p values are highly signiﬁcant even for very low correlation coefﬁcients ( r = 0.10, p < 0.01); the absolute 
value of the correlation coefﬁcient is a more conservative estimation of association: ∗Weak correlation 0.20–0.35; ∗∗Moderate correlation 
0.36–0.67; ∗∗∗Strong correlation: 0.68–1.0. 
Table 3 Model ﬁt results from CFA on negative symptoms as assessed by the Brief Negative Symptom Scale (BNSS). 
Model Number of distinct 
parameters to be estimated 
AIC BIC X 2 value (df) TLI CFI RMSEA 
1 Factor 36 962.464 966.447 890.5 (54) .531 .676 .250 
2 Factor 37 490.028 494.122 416.0 (53) .793 .859 .166 
5 Factor 46 200.100 205.190 108.1 (44) .956 .975 .077 
Hierarchical 42 200.083 204.730 116.1 (48) .957 .974 .076 
CFA = conﬁrmatory factor analysis; AIC = Akaike information criterion; BIC = Bayesian information criterion; CFI = conﬁrmatory ﬁt index; 
RMSEA = root mean square error of approximation; TLI = Tucker Lewis index. 
Table 4 Frequency of negative symptoms of moderate severity in the whole study sample ( N = 249). 
A) BNSS B) PANSS 
Negative symptoms Frequency % Negative symptoms Frequency % 
At least 1 147 59 At least 1 128 51.4 
At least 2 107 43 At least 2 78 31.3 
At least 3 73 29 At least 3 68 27.3 
Anhedonia 79 31.7 N/A 
Blunted affect 90 36.1 Blunted affect (N1) 96 38.6 
Avolition 100 40.2 Emotional withdrawal (N2) 62 24.9 
Asociality 70 28.1 Passive social withdrawal (N4) 64 25.7 
Alogia 60 24.1 Lack of spontaneity (N6) 52 20.9 
N/A Poor rapport (N3) 31 12.4 
BNSS = Brief Negative Symptom Scale; PANSS = Positive and Negative Syndrome Scale. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Results of the CFA analyses are reported in Table 3 . The
1-factor and 2-factor models provided poor ﬁt, while the 5-
factor model and the hierarchical model provided the best
ﬁt, with a small advantage of the 5-factor ﬁt. 
3.3. Frequency of negative symptoms of at least 
moderate severity 
Frequency of at least moderate severity ( ≥3) negative
symptoms for the ﬁve BNSS subscales in the whole sample
are presented in Table 4 A. One hundred and forty-seven
subjects (59%) had a score ≥3 for at least one negative
symptom on the BNSS scale. Frequency of the negativesymptoms of moderate severity (score ≥4), evaluated using
PANSS ﬁve core items is reported in the Table 4 B: 128
subjects (51.4%) showed at least one negative symptom
of moderate severity. The frequency of each negative
symptom was systematically higher using the BNSS versus
the PANSS ( Table 4 A and B). 
The frequency of at least moderate severity negative
symptoms was higher in males than in females using either
the BNSS or the PANSS ( Tables 5A and 5B ). 
The frequency of negative symptoms of moderate sever-
ity in subjects with and without confounding factors is re-
ported in Table 6 A and B, respectively. In both subgroups,
BNSS identiﬁed more subjects with at least 1 or 2 nega-
tive symptoms than the PANSS; the difference between the
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Table 5A Frequency of at least moderate severity negative symptoms using the Brief Negative Symptom Scale (BNSS) in the whole 
study sample and in male and female subsamples. 
BNSS subscale Frequency in the whole sample: N (%) Frequency in males (M) and females (F): N (%) 
Anhedonia 79/249 (31.7) M: 64/158 (40.5) 
F: 15/91 (16.5) 
Asociality 70/249 (28.1) M: 54/158 (34.2) 
F: 16/91 (17.6) 
Avolition 100/249 (40.2) M: 70/158 (44.3) 
F: 30/91 (33) 
Blunted affect 90/249 (36.1) M: 69/158 (43.7) 
F: 21/91 (23.1) 
Alogia 60/249 (24.1) M: 45/158 (28.5) 
F: 15/91 (16.5) 
Table 5B Frequency of the different negative symptoms with at least moderate severity using the Positive and Negative Syndrome 
Scale (PANSS) in the whole study sample and male and female subsamples. 
PANSS item Frequency in the whole sample: N (%) Frequency in males (M) and females (F): N (%) 
Blunted affect (N1) 96/249 (38.6) M: 73/158 (46.2) 
F: 23/91 (25.3) 
Emotional withdrawal (N2) 62/249 (24.9) M: 46/158 (29.1) 
F: 16/91 (17.6) 
Poor rapport (N3) 31/249 (12.4) M: 23/158 (14.6) 
F: 8/91 (8.8) 
Passive social withdrawal (N4) 64/249 (25.7) M: 49/158 (31) 
F: 15/91 (16.5) 
Lack of spontaneity (N6) 52/249 (20.9) M: 39/158 (24.7) 
F: 13/91 (14.3) 
Table 6 Frequency of negative symptoms of moderate severity in the subgroups with and without confounding factors such as 
positive symptoms, disorganization, depression and extrapyramidal symptoms. 
A) Subgroup with confounding factors 
( N = 113) 
B) Subgroup without confounding 
factors ( N = 136) 
BNSS PANSS BNSS PANSS 
N (%) N (%) 
At least 1 negative symptom 79 (69.9) 74 (65.5) 68 (50) 54 (39.7) 
At least 2 negative symptoms 58 (51.3) 47 (41.6) 49 (36) 31 (22.8) 
At least 3 negative symptoms 44 (38.9) 40 (35.4) 29 (21.3) 28 (20.6) 
BNSS = Brief Negative Symptom Scale; PANSS = Positive and Negative Syndrome Scale. 
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mcales was negligible for the identiﬁcation of subjects with 
t least 3 negative symptoms (i.e., the most severely af-
ected subjects). 
.4. Impact of negative symptoms on functional 
utcome 
able 7 illustrates the results of the multiple stepwise re-
ression analyses on PSP total score. 
When the negative symptoms assessed using the ﬁve 
NSS subscales were entered among the independent pre- 
ictors ( Table 7 A), the model was signiﬁcant (adjusted
 
2 = 0.387, p < 0.00001) and accounted for approximately
9% of the variance of PSP total score. Lower functional out-
ome was predicted by higher avolition scores ( β = −0.404, < 0.00001), which accounted for most of the explained
SP variance (29.3/39%), higher disorganization and posi- 
ive dimension scores ( β = −0.193, p = 0.009, β = −0.154,
 = 0.026, respectively) and male gender ( β = 0.134,
 = 0.015). The other independent variables (age, educa-
ion, duration of illness, olanzapine equivalent dose, the 
ther negative symptoms, depression, SHRS Parkinsonism) 
id not enter the regression equation. 
The regression model was also signiﬁcant when the neg-
tive symptoms were evaluated using PANSS ﬁve core items
adjusted R 2 = 0.378, p < 0.00001) and accounted for ap-
roximately 38% of the variance of functional outcome 
 Table 7 B). In the regression analysis, lower functional out-
ome was predicted by higher scores on disorganization 
imension ( β = −0.238, p = 0.001), which accounted for
ost of the explained PSP variance (21.4/37.8%), Passive 
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Table 7 Results of multiple regression analyses on Personal and Social Performance (PSP) total score in subjects with schizophrenia 
to investigate the impact of negative symptoms on functioning. 
A) Negative symptom domains from the BNSS 
Variables entering the equation R square change Beta T P 
BNSS avolition 0.297 −0.404 −6.378 < 0.00001 
PANSS disorganization 0.071 −0.193 −2.628 0.009 
Gender 0.017 0.134 2.449 0.015 
PANSS positive 0.015 −0.154 −2.239 0.026 
Variables not entering the equation R square change Beta T P 
BNSS anhedonia NA 0.050 0.639 0.524 
BNSS asociality NA −0.008 −0.100 0.920 
BNSS blunted affect NA −0.115 −1.630 0.105 
BNSS alogia NA 0.022 0.325 0.746 
Age NA 0.005 0.089 0.930 
Education NA 0.087 1.515 0.131 
Duration of illness NA 0.016 0.285 0.776 
Olanzapine equivalent dose NA −0.027 −0.480 0.632 
Depression NA 0.035 0.609 0.543 
SHRS Parkinsonism NA −0.060 −1.049 0.295 
The regression model was signiﬁcant (adjusted R 2 = 0.387, p < 0.00001) and accounted for approximately 39% of the PSP total 
variance. 
B) Negative symptom domains from the PANSS 
Variables entering the equation R square change Beta T P 
PANSS disorganization 0.218 −0.238 −3.245 0.001 
Passive social withdrawal (N4) 0.105 −0.232 −3.529 0.001 
Poor rapport (N3) 0.023 −0.179 −2.722 0.007 
Gender 0.017 0.134 2.398 0.017 
PANSS positive 0.015 −0.156 −2.221 0.027 
Variables not entering the equation R square change Beta T P 
PANSS blunted affect (N1) NA −0.024 −0.310 0.756 
PANSS emotional withdrawal (N2) NA −0.099 −1.138 0.257 
PANSS lack of spontaneity (N6) NA 0.094 1.197 0.233 
Age NA −0.052 −0.908 0.365 
Education NA 0.105 1.788 0.075 
Duration of illness NA −0.041 −0.691 0.491 
Olanzapine equivalent dose NA −0.057 −1.014 0.312 
Depression NA 0.021 0.351 0.726 
SHRS Parkinsonism NA −0.075 −1.298 0.196 
The regression model was signiﬁcant (adjusted R 2 = 0.378, p < 0.00001) and accounted for approximately 38% of the PSP total 
variance. 
In A) the 5 subscales of the Brief Negative Symptom Scale (BNSS) were included as independent predictors, while in B) the 5 core negative 
symptom items of the Positive and Negative Syndrome Scale (PANSS) were included. The negative standardized beta for all continuous 
independent predictors indicates that higher severity of psychopathology is associated with lower scores on PSP (i.e., poorer functioning). 
Male gender was associated with lower PSP scores than female gender. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Social Withdrawal ( β = −0.232, p = 0.001), Poor Rapport
( β = −0.179, p = 0.007), male gender ( β = 0.134, p = 0.017)
and higher positive scores ( β = −0.156, p = 0.027). The two
negative symptoms accounted for about 12% of the PSP vari-
ance. The other independent variables (age, education, du-
ration of illness, olanzapine equivalent dose, the other neg-
ative symptoms, depression and SHRS Parkinsonism) did not
enter the regression equation. 
3.5. Control analyses 
As control analyses, to evaluate the comparability of
BNSS across countries/languages, we assessed the pres-
ence of a center effect on: (1) the frequency of negativesymptoms, as evaluated by the BNSS and PANSS; (2) the
correlations of the BNSS and PANSS core negative symp-
tom totals; (3) the correlations of the PSP total score with
the BNSS and PANSS core negative symptom total scores.
As reported in Table S1 of the supplemental materials,
in all centers the frequency of negative symptoms of at
least moderate severity was higher using the BNSS than
the PANSS, except in two centers in which it was compa-
rable. All centers showed a positive correlation between
BNSS and PANSS core negative symptom totals > 0.70 (Table
S2). As to the correlations of the PSP total with both BNSS
and PANSS core negative symptoms (Table S3), all centers
showed a negative association, although in some centers
the association was not signiﬁcant. However, the difference
between the highest and lowest correlation coefﬁcients
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eas not signiﬁcant ( z = 2.78/2.05; p > 0.05 Bonferroni cor-
ected). 
. Discussion 
ain results of our study included: (1) the demonstration 
f high internal consistency, convergent and divergent va- 
idity of the BNSS in a large sample of subjects with clin-
cally stable, chronic schizophrenia, within a multicenter, 
ultinational, large European study; (2) the validation of 
he 5-factors structure of negative symptoms as assessed 
y the BNSS; (3) the demonstration that BNSS consistently 
dentiﬁes more subjects with negative symptoms compared 
o PANSS, in the whole sample, as well as in males and fe-
ales, and in subjects with and without confounding fac- 
ors; (4) the demonstration that avolition, a negative symp- 
om domain poorly assessed by PANSS, has a larger impact
n a measure of functional outcome (the PSP total score) as
ompared with the core negative items of the PANSS. 
While the majority of the studies evaluated negative 
ymptoms with the items of the PANSS negative subscale 
r with the SANS ( Galderisi et al., 2013b , 2018a; Rocca
t al., 2014; Lincoln et al., 2017; Strassnig et al., 2018 ),
n our study we assessed the severity of negative symptoms 
ith BNSS. The latter instrument has several advantages: 
t provides a rapid assessment of negative symptoms based 
n a semi-structured interview and does not include symp- 
oms formerly regarded as part of the negative dimension 
ut now clearly identiﬁed as aspects of other dimensions, 
uch as the cognitive or depressive one ( Bucci and Galderisi,
017 ). The results of this multicenter, multinational study, 
n line with other studies, showed high internal consistency 
 Strauss et al., 2012c ) and validity of the BNSS across differ-
nt countries/languages ( Ahmed et al., 2018 ). Furthermore, 
e conﬁrmed the 5-factor structure of negative symptoms 
n agreement with Strauss et al. (2018a) and Ahmed et al.
2018) . 
Our results demonstrated a greater sensitivity of BNSS in 
he detection of negative symptoms compared to the PANSS: 
n particular, the PANSS has a smaller number of items to
valuate subdomains of negative symptoms and does not 
ontain items for an adequate evaluation of anhedonia and 
volition ( Marder and Galderisi, 2017 ). 
Our data conﬁrm that the BNSS, developed speciﬁcally 
ollowing the NIMH-MATRICS Consensus Development Con- 
erence on negative symptoms ( Kirkpatrick et al., 2006 ; 
irkpatrick et al., 2011 ), may represent a valuable tool for a
ore accurate evaluation of negative symptoms, compared 
o the PANSS. 
Our criteria for selection of the sample of subjects with-
ut confounding factors were in line with the EMA guide-
ines on drug approval for negative symptoms, requiring 
hat major confounding factors, i.e. extrapyramidal symp- 
oms and depression, have to be excluded and were also 
n line with the concept of “Predominant negative symp- 
oms” (i.e., excluding positive symptoms from moderate- 
evere to extremely severe). In this sample, representing 
he ideal target of clinical trials on negative symptoms, the
NSS demonstrated advantages over the PANSS, as it iden- 
iﬁed a larger number of subjects with at least moderate
everity negative symptoms. These ﬁndings are probably re- ated to the identiﬁcation of subjects with moderate sever-
ty of avolition and anhedonia, which are not assessed by the
ANSS. Our results also demonstrated that the advantage of
he BNSS was larger for subjects with only 1 or 2 moder-
te severity negative symptoms, suggesting the possibility 
o lower the entry cutoff for clinical trials. Of course, this
mplication needs further testing. 
As to the impact of negative symptoms on patients’ func-
ional outcome, several studies conﬁrmed that in particular 
he avolition \ asociality factor (including all or some of the
omains of avolition, asociality and anhedonia) is a stronger
redictor than the expressive deﬁcit factor, which includes 
logia and blunted affect ( Fervaha et al., 2013; Galderisi
t al., 2014; Green et al., 2012; Harvey et al., 2017; Rocca
t al., 2014; Ventura et al., 2015 ). However, the factor ex-
racted using the PANSS often included items which are not
ore negative symptoms and might overlap with positive and
isorganization dimensions or cognitive dysfunctions (e.g., 
16-Active social avoidance that rates the avoidance of so-
ial contacts due to positive symptoms or anxiety, or G13-
volition which rates the indecisiveness in engaging in goal-
irected action due to disorganization or cognitive impair- 
ent). In our study, we decided to evaluate the impact of
ore negative symptom domains, assessed either by BNSS 
r PANSS, to investigate whether the newer scale identi-
ed one or more domains with larger functional impact. Our
esults showed that the avolition domain assessed by BNSS
as more efﬁcient than any combination of PANSS-assessed 
egative symptom domains in predicting functional out- 
ome. The avolition domain consistently loaded on the avo-
ition/apathy factor ( Kirkpatrick et al., 2011; Mucci et al.,
015; Strauss et al., 2012a ) and represents the domain with
he largest impact on outcome. The two domains assessed 
y PANSS which entered the regression equation were Pas-
ive social withdrawal and Poor rapport. The ﬁrst one, which
onsistently loaded on the avolition/apathy factor in pre- 
ious studies, explained the largest proportion of variance 
though half the proportion explained by the BNSS-assessed 
volition), while the expressive-related domain, Poor rap- 
ort, only explained a small proportion of the PSP variance
about 2%). 
This ﬁnding, together with the identiﬁcation by BNSS of
 larger number of subjects with unconfounded negative 
ymptoms, has implications for the choice of the assessment 
nstrument in clinical trials devoted to the development of
nnovative treatments for negative symptoms. Avolition is 
oorly deﬁned using the PANSS: in fact, only N4-Emotional
ithdrawal assesses the level of interest and engagement 
n goal-directed activities, as inferred by the behavior of
he subject. Instead, BNSS has 2 items assessing both be-
avior and internal experience, thus capturing the nuclear 
spect of avolition that is the lack of motivation and inter-
st for initiation and maintenance of goal-directed behavior 
 Galderisi et al., 2018a ). 
Reaching a deeper understanding of the negative symp- 
om constructs could contribute to develop personalized 
reatment strategies aimed at improving functioning in sub- 
ects with schizophrenia. Until now, both pharmacological 
nd psychotherapeutic options to treat negative symptoms 
ave been unsatisfactory ( Galderisi et al., 2018a; Kesha-
an et al., 2017; Sarkar et al., 2015; Talpos, 2017; Veerman
t al., 2017 ). 
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 The results of our study should be considered in the light
of some limitations. First, we cannot make inferences on
the direction of the observed effects due to the cross-
sectional design; second, we cannot disentangle the role of
neurocognitive deﬁcits on functioning, a relationship that
is widely reported in the literature ( Galderisi et al., 2014 ,
2018a , 2018b ; Leifker et al., 2009 ), due to the lack of a
neurocognitive assessment; third, the experimental sam-
ple consisted of chronic and clinically stable subjects with
schizophrenia and did not include patients in the acute
phase or earlier in the course of the illness, thus preventing
the generalizability of our ﬁndings. 
The inter-rater reliability across-centers was not assessed
for this study. However, as reported in the Supplementary
materials, all centers involved in this study showed com-
parable data and results concerning the frequency of neg-
ative symptoms of at least moderate severity, the correla-
tions between BNSS and PANSS, and the correlations of the
PSP total with both BNSS and PANSS, thus suggesting a high
reproducibility and reliability of the assessments. 
In conclusion, our study supports the validity of the BNSS,
within a large European multicenter, multinational, multi-
lingual study. The results show that BNSS, with respect to
the core PANSS negative symptoms, identiﬁes a larger num-
ber of subjects with at least one or with at least two nega-
tive symptoms of moderate severity, particularly in subjects
without confounding factors. Finally, avolition, as identiﬁed
by BNSS, has a stronger association with functional out-
come, with respect to any combination of core negative
symptoms identiﬁed by PANSS. Our ﬁndings support the use
of the BNSS in future clinical trials focusing on negative
symptoms. 
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